TrippBio, a biotechnology company, is producing a patent-pending repurposed FDA-approved drug called TD213 intended for the treatment of viral infections, initially targeting COVID-19, it was reported on Monday.

TD213 is administered orally twice daily and works by halting the SARS-CoV-2 virus and the associated acute inflammatory response to the infection.

The firm has revealed positive interim data from the investigator-initiated study to evaluate the efficacy of the product in treating patients with confirmed mild-moderate COVD-19.

Dr Moti N. Ramgopal of Midway Immunology and Research Center conducted the study. Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were administered the product twice daily for 14 days and will be followed until day 28.